ERAS
Erasca, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.62
+1.72%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -4.1%
- EPS
- —
- Free cash flow
- +1.1%
- Operating cash flow
- +1.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +38.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- +20.8%
- EBIT
- +26.8%
- Net income
- +23.0%
- EPS
- +36.2%
- Free cash flow
- +27.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026